Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

These Oil and Biotech Stocks Are in the Crosshairs of Elite Investors

Page 1 of 2

While many hedge funds are still preparing their third quarter filings with the SEC, providing the main ingredients for our delectable small-cap investment strategy, some managers are already disclosing even more recent moves. The latest wave of filings includes two oil and gas companies, and one biotech stock. Let’s analyze the deals and also how other hedge funds are positioned with regard to these stocks.

John Scully - SPO Advisory Corp

Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35%-to-45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is when it comes to purchases made by corporate insiders. Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012. We have been forward testing the performance of these stock picks since the end of August 2012 and they have returned 102% over the ensuing 37 months, outperforming the S&P 500 Index by over 53 percentage points (read the details here). The trick is focusing only on the best small-cap stock picks of funds, not their large-cap stock picks which are extensively covered by analysts and followed by almost everybody.

John H. Scully has decided to further reduce his exposure to Resolute Energy Corp (NYSE:REN), with his fund, SPO Advisory Corp having reported the disposal of 2 million shares in a recent Form 4 filing with the Securities and Exchange Commission. As a result, the fund now holds approximately 14.9 million shares, the equivalent of 19.3% of the company’s common stock. Resolute Energy Corp (NYSE:REN) gained popularity among top hedge funds during the second quarter, with the number of funds reporting long positions in the stock as of the end of June increasing to 15, while their combined holdings accounted for 40% of Resolute’s outstanding stock. Edward Gilhuly and Scott Stuart, the managers of Sageview Capital, are also betting big on Resolute Energy, having reported ownership of 5.07 million shares as of the end of the second quarter.

John H. Scully
John H. Scully
SPO Advisory Corp

Resolute Energy Corp (NYSE:REN) has been a terrible performer so far this year, having lost nearly 62% of its value year-to-date. The stock has been severely hit by the slump in the energy market, having traded around the $8 level in July 2014 before oil prices started to slide. Revenues were also affected, with Resolute Energy reporting $48.4 million in revenues for the second quarter of 2015, down by 45% year-over-year, and a loss of $0.66 per share, triple the loss reported for the second quarter of 2014. Analysts expect the situation to improve however, having estimated revenues of $54.9 million and a loss of $0.12 per share for the current quarter, with Resolute Energy set to release its latest financial report on November 9.

Follow Resolute Energy Corp (NYSE:REN)
Trade (NYSE:REN) Now!
Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!